Abstract: A method is provided for treating hematologic tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an MTP inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematologic tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.

Abstract: The malodours of an ostomy bag are reduced by including therein an article including a hygroscopic matrix and additive. The matrix is selected from polyethylene glycol, polypropylene glycol and glycerol. The additive is selected from food preservatives, fragrances, disinfectants, and odor absorbers.

Abstract: A method for decreasing metalloproteinase activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. Also, a method for increasing TIMP activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. In addition a method for inhibiting or treating progression of a tumor in a patient that comprises the step of administering to said patient a therapeutic composition comprising oncostatin-M, or a biologically active fragment, mutant, analog, or fusion construct thereof, said method being effective to inhibit invasion by a tumor cell through an extracellular space, extracellular matrix, basement membrane, interstitial tissue or connective tissue.

Abstract: Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses.

Abstract: The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.

Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:x is --ONR.sup.1 C(O)--, --N(OR.sup.1)C(O)--, --NR.sup.1 C(O)--, --C(O)NR.sup.1 --, --NR.sup.1 S(O.sub.2)--, --C(O)O--, --OC(O)--, --C(O)--, --O--, --NR.sup.1 -- or --(S).sub.q --;Y is --CO.sub.2 R.sup.2, --SO.sub.3 R.sup.2 or --P(O) (OR.sup.2) (R.sup.3);R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenylene or aryl;R.sup.3 is --(O).sub.t R.sup.4 ;R.sup.1, R.sup.2 and R.sup.4 are each independently hydrogen, alkyl, aryl or aralkyl;m and n are each independently 0 or an integer from 1 to 5;p and t are each independently 0 or 1; andq is an integer from 1 to 2.

Abstract: A novel series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones having enhanced water solubility bioavailability and metabolic stability is disclosed in the Formula I ##STR1## wherein R.sup.1 is H, or C.sub.1 -C.sub.4 lower alkyl;R.sup.2 is H, (CH.sub.2).sub.m R.sup.3 ; benzoxazol-2yl, or benzothiazol2-yl;R.sup.3 is C.sub.1 -C.sub.8 alkyl, C.sub.4 -C.sub.8 cycloalkyl, or substituted or unsubstituted phenyl, wherein the substituents are halogen, alkoxy or trifluoromethyl;m is an integer of 1-3; andn is an integer of 1-5;or pharmaceutically acceptable salt thereof.The compounds are useful as inhibitors of ADP-induced blood platelet aggregation in human platelet-rich plasma.

Abstract: Presented is an endoprosthesis for the partial replacement of the joint head of a human bone, in particular of the thigh bone, that includes a first spherical segment whose diameter corresponds to the upper part of the natural joint head. Serving for anchoring the endoprosthesis in the human bone is an anchoring part that adjoins the first spherical segment and that is constructed as a second spherical segment that is capable of being anchored in a corresponding spherical recess in the bone.

Abstract: A fermentation process for preparing staurosporine, a known antibiotic, employing a heretofore unknown micrrorganism is described, said microorganism being classified as a novel strain of Streptomyces hygroscopicus being and herein designated Streptomyces hygroscopicus strain C39280-450-9 (ATCC 53730).